BIO 300 Oral Suspension

DRUG3 trials

Sponsors

Humanetics Corporation

Conditions

COVID-19Carcinoma, Non-Small-Cell LungHealthy Volunteer StudyLong COVIDPost-acute Respiratory Complications of COVID-19Pulmonary Fibrosis

Phase 1

BIO 300 Non-Small Cell Lung Cancer Study

CompletedNCT02567799

Humanetics CorporationCarcinoma, Non-Small-Cell Lung

Start: 2015-11-30End: 2020-09-30Updated: 2024-01-25

Phase 1 BIO 300 Oral Suspension

CompletedNCT06741345

Humanetics CorporationHealthy Volunteer Study

Start: 2024-12-23End: 2025-08-15Updated: 2025-10-30

Phase 2

BIO 300 Oral Suspension in Previously Hospitalized Long COVID Patients

Active, not recruitingNCT04482595

Humanetics CorporationCOVID-19, Long COVID, Post-acute Respiratory Complications of COVID-19 +1

Start: 2020-11-11End: 2025-04-30Target: 50Updated: 2024-10-01